Research
Molecular
Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will inform clinical practice on safe and effective ways to reduce cardiovascular risk in T2DM.
Healthcare providers should stay updated on findings from these trials to optimize T2DM treatment strategies.
StrongSupportsmedium confidence
Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will continue to inform clinical practice on safe and effective ways to reduce CV risk in T2DM.
Why this rating
The mention of ongoing trials indicates a robust evidence base.
Source
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Karan Kapoor et al. · Cardiology · 2016
reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →